OBIO - Latest News
Orchestra BioMed Holdings, Inc. (OBIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $342.5M. Beta to the broader market is 0.52.
The article list below shows the most recent OBIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent OBIO Headlines
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
globenewswire.com - Oct 1, 2026
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to
OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures
businesswire.com - Sep 29, 2026
TORONTO--(BUSINESS WIRE)--OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capita
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
zacks.com - Sep 21, 2026
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume.
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
globenewswire.com - Sep 16, 2026
NEW HOPE, Pa. , Sept.
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
globenewswire.com - Sep 15, 2026
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains
How News Affects OBIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track OBIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked OBIO news questions
- What is the latest OBIO news headline?
- The most recent OBIO headline (Oct 1, 2026) is "Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the OBIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What OBIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual OBIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.